Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma.

Cancer research - 14 Aug 2026

Garcia Borrego Santiago, Misale Sandra

Abstract excerpt

Mutant KRAS inhibition has revolutionized the treatment of lung adenocarcinoma. Unfortunately, responses to this form of targeted therapy are often of limited duration because of the development of resistance. Targeted protein degradation, including using PROTACs (PROteolysis-TArgeting Chimeras), presents an alternative approach to targeting oncogenic drivers in cancer. In this issue of Cancer Research, Martín...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Proteolysis

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 42596691
DOI: 10.1158/0008-5472.CAN-26-2186

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma.PMID 42596691Read ↗

Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer modelsSemantic proximity Read ↗

Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment.Semantic proximity Read ↗

Research progress of direct and indirect KRAS-targeting protein degraders in KRAS-mutant cancers.Semantic proximity Read ↗

Proteolysis targeting chimeras in non-small cell lung cancer.Semantic proximity Read ↗

Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 LigasesSemantic proximity Read ↗

Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung CancerSemantic proximity Read ↗

[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].Semantic proximity Read ↗

Increased dosage of wild-type KRAS protein drives <i>KRAS</i> -mutant lung tumorigenesis and drug resistanceSemantic proximity Read ↗

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.Semantic proximity Read ↗

Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.Semantic proximity Read ↗

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinomaSemantic proximity Read ↗

Recent advances in targeted degradation in the RAS pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.